Andrew (Andy) Eisen earned his MD and PhD (Biophysics) from the University of Pennsylvania and completed a residency in Pediatrics at the Children’s Hospital of Philadelphia. He next did a fellowship in Clinical and Molecular Genetics at NIH. This was followed by an academic appointment at The Albert Einstein College of Medicine where his lab focused on developing gene targeting technologies before entering the biotech sector 20 years ago. Initially, he joined CuraGen where his team utilized genomics to identify new targets for small molecule drug development. In turn he spent time at Daiichi-Sankyo, Eisai, Acorda and Rexahn developing biomarker and Translational Medicine strategies to advance small molecules and biologics across diverse therapeutic areas in First-In-Humans (Ph 1) through Proof-of-Concept (Ph 2) clinical trials. He looks forward to the new clinical challenge of developing the gene and cellular therapies in immune-oncology at Immunomic Thereapeutics.